2,3-DIHYDROBENZOFURAN-5-BORONIC ACID – (227305-69-3)

Canertinib, 267243-28-7, CI-1033, Canertinib (CI-1033), PD-183805, Canertinib free base, N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide, N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide, N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide, C78W1K5ASF, CHEMBL31965, DTXSID8048943, CHEBI:61399, 267243-28-7 (free base), N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide, NCGC00182713-01, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide, Canertinib [INN], Canertinib [INN:BAN], CI-1033(Canertinib), UNII-C78W1K5ASF, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide, CANETINIB, CANERTINIB [MI], Caneritinib CI-1033, CI-1033 (Canertinib), CANERTINIB [WHO-DD], SCHEMBL54837, MLS004774146, PD 183805 dihydrochloride, BDBM4779, cid_156414, GTPL5675, DTXCID1028869, EX-A078, OMZCMEYTWSXEPZ-UHFFFAOYSA-N, BCPP000301, HMS3244M17, HMS3244M18, HMS3244N17, BCP01790, Tox21_113361, NSC780019, NSC801011, s1019, AKOS005145818, BCP9000481, BCP9000482, BCP9000525, CCG-269588, CS-0121, DB05424, NSC-780019, NSC-801011, SB16594, SDCCGSBI-0654262.P002, N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide, NCGC00182713-02, NCGC00182713-18, AS-56189, HY-10367, SMR003500789, PD0183805, CAS-267243-28-7, NS00071801, EN300-6493001, Q5032274, BRD-K50168500-001-07-9, Z166624030, 2-PROPENAMIDE, N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-(3-(4-MORPHOLINYL)PROPOXY)-6-QUINAZOLINYL)-, N-(4-(3-CHLORO-4-FLUOROPHENYL)AMINO)-7-(3-MORPHOLIN-4-YL)PROPOXY)QUINAZOLIN-6-YL)PROP-2-ENAMIDE, N-[4-(3-chloro-4-fluoro-phenyl-amino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide